Sarcopenia and interleukin-23 in colorectal cancer survival

  • Shupeng Gao
    Affiliations
    Medical Records Department, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
    Search for articles by this author
  • Yan Li
    Correspondence
    Corresponding author. Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110033, China.
    Affiliations
    Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
    Search for articles by this author
Published:November 23, 2021DOI:https://doi.org/10.1016/j.clnu.2021.11.015
      Hu and colleagues recently investigated the association between sarcopenia, the expression level of interleukin-23 (IL-23) and the prognosis of patients with colorectal (CR) cancer [
      • Hu W.-H.
      • Chang C.-D.
      • Liu T.-T.
      • Chen H.-H.
      • Hsiao C.-C.
      • Kang H.-Y.
      • et al.
      Association of sarcopenia and expression of interleukin-23 in colorectal cancer survival.
      ]. In this study involving 114 participants, sarcopenia was found to be associated with poor disease-free survival (DFS) and overall survival (OS) after adjusting potential confounding factors. In addition, an interesting finding was that patients with sarcopenia combined with high expression of IL-23 have the worst prognosis. This study is the first to explore the interaction between sarcopenia and the expression of IL-23 on the prognosis of CR patients, which is helpful to further refine the risk stratification and improve the prognosis of CR patients. However, the following concerns need to be further clarified.
      To read this article in full you will need to make a payment
      Subscribe to Clinical Nutrition
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hu W.-H.
        • Chang C.-D.
        • Liu T.-T.
        • Chen H.-H.
        • Hsiao C.-C.
        • Kang H.-Y.
        • et al.
        Association of sarcopenia and expression of interleukin-23 in colorectal cancer survival.
        Clin Nutr. 2021; 40: 5322-5326
        • Doleman B.
        • Mills K.T.
        • Lim S.
        • Zelhart M.D.
        • Gagliardi G.
        Body mass index and colorectal cancer prognosis: a systematic review and meta-analysis.
        Tech Coloproctol. 2016; 20: 517-535
        • Campbell P.T.
        • Newton C.C.
        • Dehal A.N.
        • Jacobs E.J.
        • Patel A.V.
        • Gapstur S.M.
        Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort.
        J Clin Oncol. 2012; 30: 42-52
        • Suzuki C.
        • Blomqvist L.
        • Sundin A.
        • Jacobsson H.
        • Byström P.
        • Berglund Å.
        • et al.
        The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
        Ann Oncol. 2012; 23: 948-954
        • Dai W.
        • Li Y.
        • Meng X.
        • Cai S.
        • Li Q.
        • Cai G.
        Does tumor size have its prognostic role in colorectal cancer? Re-evaluating its value in colorectal adenocarcinoma with different macroscopic growth pattern.
        Int J Surg. 2017; 45: 105-112
        • Sorich M.J.
        • Wiese M.D.
        • Rowland A.
        • Kichenadasse G.
        • McKinnon R.A.
        • Karapetis C.S.
        Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
        Ann Oncol. 2015; 26: 13-21
        • Arnold D.
        • Lueza B.
        • Douillard J.Y.
        • Peeters M.
        • Lenz H.J.
        • Venook A.
        • et al.
        Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials †.
        Ann Oncol. 2017; 28: 1713-1729